
CDC: Skin cancer treatment costs ‘skyrocketing’
A new government study suggests costs related to nonmelanoma skin cancer and melanoma treatment have skyrocketed relative to other cancers, increasing by 126 percent to more than $8 billion.
A new government study suggests costs related to nonmelanoma
The average annual skin cancer treatment cost rose 126 percent - from $3.6 billion in 2002 to 2006, to $8.1 billion from 2007 to 2011. That’s compared to an average annual treatment cost increase of 25 percent for all other cancers during the same period.
The
When Dermatology Times asked lead author Gery Guy, Ph.D., of the CDC’s
“In the first period (2002 to 2006), about 8 percent of costs were incurred in the inpatient setting. But in the most recent period (2007 to 2011), about a third of costs were in the inpatient setting,” Dr. Guy says. “One thing this study shows is the substantial costs associated with skin cancer treatment in the United States, but it’s important to keep in mind that it also shows the potential for savings that could be accrued through
Dermatologist
“This study validates the role of screening and prevention programs as a mechanism to reduce the incidence of skin cancer and its related costs,” says Dr. Coldiron, who is in private practice in Cincinnati. “In recent years, we have seen a number of new breakthroughs for the treatment of melanoma, and these drugs are expensive, but only comprise a small part of the total cost. The majority of skin cancers are treated very cost efficiently by dermatologists in the office setting.
“The reason the cost of treating skin cancer has gone up so much is because there’s been such a big increase in the total number of skin cancers. But a patient should never bear economic hardship in order to undergo treatment for a serious disease like skin cancer - it is going to require all stakeholders to find a solution,” he says. “AAD believes we have a societal responsibility to help manage the rising cost of care - along with government agencies, insurance companies, pharmaceutical companies, patient groups and policymakers. The country’s rising healthcare costs are a complex issue, with many factors at play. Physicians are just one part of a larger cost equation.”
The study findings were published online Nov. 9 in the
Reference: Guy GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med. 9 Nov 2014 [Epub ahead of print].
Related content:
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















